MRCP Respiratory: Mastering Massive Pulmonary Embolism Guidelines

Massive pulmonary embolism (PE) is a high‑stakes, high‑yield topic in the MRCP Part 2 and PACES respiratory station. In a real‑time acute scenario, you must rapidly identify haemodynamic compromise, initiate life‑saving treatment, and navigate complex risk stratification. This guide condenses contemporary UK guidelines, national and international consensus statements, and exam‑tested pathways so you can perform decisively under pressure.

1) Clinical Recognition: Who Has a Massive PE?

• haemodynamic instability:

  • systolic BP <90 mmHg for ≥15 minutes OR drop ≥40 mmHg (not due to new arrhythmia, hypovolaemia, or sepsis),

  • or need for inotropes/vasopressors, OR

  • cardiac arrest.

• often preceded by dyspnoea, pleuritic chest pain, cough, or syncope.

• risk factors: recent surgery/travel, cancer, thrombophilia, immobility, estrogen therapy, pregnancy/post‑partum.

• exam cue: a shocked, hypoxic patient with signs of right heart strain on bedside echo.

2) Immediate Actions in the First 5 Minutes

• Airway, breathing, circulation.

• High‑flow O2 (target SpO2 94–98%; 88–92% if CO2 retention risk).

• Large‑bore IV access; cardiac monitoring.

• Send arterial blood gas, FBC, U&E, LFT, coagulation profile, troponin, BNP/NT‑proBNP.

• 12‑lead ECG: sinus tachycardia most common; RV strain patterns (S1Q3T3, incomplete RBBB, T‑wave inversion V1–V4) may be present but are insensitive.

• Portable CXR: may show Hampton’s hump or Westermark sign but frequently normal—don’t delay diagnostics because of a clear CXR.

• Urgent bedside echo: RV dilation, hypokinesis, McConnell’s sign (RV free wall hypokinesis with apical sparing) supports PE.

• Do NOT wait for D‑dimer in haemodynamically unstable patients—proceed to CT pulmonary angiography (CTPA) if haemodynamically stable enough, or to immediate echocardiography and reperfusion if not.

3) Risk Stratification

3.1 Clinical Risk Scores

• Wells score (simplified) and Geneva score can support clinical gestalt. High pre‑test probability in the context of shock strongly supports massive PE.

• PERC rule excludes testing in outpatients with very low pre‑test probability—do not apply if haemodynamic compromise is present.

3.2 Imaging and Labs for Severity

• CTPA: preferred if the patient can safely be scanned; right/left ventricular diameter ratio (RV/LV) >1 on CT predicts adverse outcomes.

• Bedside echo: evidence of RV dysfunction strongly predicts mortality.

• Biomarkers: elevated troponin and BNP/NT‑proBNP reflect RV injury and strain and help identify intermediate‑high risk.

3.3 The Exam Algorithm You Must Know

• Suspected massive PE with haemodynamic instability: if the patient is too unstable for CTPA, perform urgent bedside echo. If echo shows RV dysfunction and no other cause for shock, proceed to thrombolysis. If thrombolysis fails or is contraindicated, move to catheter‑directed therapy or surgical embolectomy.

• If the patient can tolerate transport, CTPA confirms diagnosis before reperfusion.

4) Management: Massive (High‑Risk) PE

• Anticoagulation should not delay reperfusion in massive PE. Start weight‑adjusted unfractionated heparin (UFH) infusion immediately while arranging definitive therapy unless a clear contraindication exists.

4.1 Systemic Thrombolysis

• First‑line reperfusion for most patients with massive PE and no absolute contraindications.

• Alteplase regimen commonly used: 10 mg IV bolus over 1–2 minutes followed by 90 mg infusion over 2 hours (maximum total 100 mg). Some centres use a 50 mg fixed dose.

• If thrombolysis fails (persistent shock/inotropy) or is contraindicated, move to catheter‑based or surgical rescue.

4.2 Catheter‑Directed Therapy (CDT)

• Options: catheter‑directed thrombolysis (CDT) at reduced tPA doses; mechanical thrombectomy; or combined pharmacomechanical therapy.

• Use in patients with contraindications to systemic thrombolysis or when thrombolysis has failed.

4.3 Surgical Embolectomy

• Consider in:

  • thrombolysis contraindicated or failed,

  • trapped right heart thrombus,

  • severe haemodynamic compromise when CDT not available.

• Requires cardiopulmonary bypass and expertise.

4.4 Haemodynamic Support

• Cautious fluid: avoid volume overload in RV failure—250–500 mL crystalloid challenge if hypovolaemic.

• Vasopressors: noradrenaline is first‑line for hypotension; use sparingly to maintain perfusion without excessive pulmonary vasoconstriction.

• Inotropes: dobutamine may improve RV contractility in low‑output states.

• ECMO: consider veno‑arterial ECMO as a bridge to embolectomy or recovery in refractory cardiogenic shock where expertise and rapid deployment are available.

4.5 Anticoagulation After Reperfusion

• Start/continue UFH in acute phase; transition to a direct oral anticoagulant (DOAC) in haemodynamically stable patients once clinically appropriate and no contraindications.

• DOACs (licensed for PE): apixaban, edoxaban, rivaroxaban, dabigatran.

• Typical regimens:

  • Rivaroxaban: 15 mg twice daily with food for 21 days, then 20 mg once daily.

  • Apixaban: 10 mg twice daily for 7 days, then 5 mg twice daily.

  • Edoxaban or dabigatran require initial parenteral heparin overlap.

• Continue anticoagulation for at least 3 months; extended therapy depends on provoked vs unprovoked PE, bleeding risk, and cancer status.

5) Contraindications to Thrombolysis (Relative vs Absolute)

• Common absolute contraindications:

  • active internal bleeding,

  • recent intracranial/intraspinal surgery (<2 months) or trauma,

  • intracranial neoplasm, AV malformation, or aneurysm,

  • recent ischaemic stroke (<3–6 months),

  • suspected aortic dissection,

  • bleeding diathesis (e.g., significant thrombocytopenia).

• Relative contraindications include uncontrolled hypertension, recent major surgery (<3–10 days), pregnancy, and advanced age. In massive PE with impending death, the balance shifts toward reperfusion despite relative contraindications—document rationale and discuss risks.

6) Investigations: Targets vs Distraction

• Always send troponin and BNP/NT‑proBNP alongside baseline labs; abnormal values help risk‑stratify but do not replace haemodynamic assessment.

• D‑dimer is unhelpful in haemodynamically unstable patients—don’t wait for it.

• Lower‑extremity Doppler ultrasound can identify proximal DVT if CTPA cannot be performed quickly.

7) Common Pitfalls to Avoid in MRCP

• Don’t delay reperfusion to wait for CTPA when the patient is in shock with echo evidence of RV strain and no alternative explanation.

• Don’t overload with fluids in RV failure.

• Don’t miss the diagnosis in patients with “normal” CXR—PE can present without focal radiographic signs.

• Don’t forget to document the thrombolysis decision and contraindications carefully; your reasoning will be scrutinised.

• Don’t leave the patient on high‑dose noradrenaline indefinitely; plan definitive reperfusion or escalation.

8) MRCP‑Focused OSCE/PACES Tips

• Structure your answer: “I suspect massive PE in a shocked patient. I would give high‑flow oxygen, obtain urgent IV access, order ABG, troponin, BNP, baseline coagulation, and arrange immediate bedside echo. If the echo shows RV dysfunction with no other cause of shock and the patient is too unstable for CTPA, I would proceed to systemic thrombolysis while initiating UFH. If thrombolysis fails or is contraindicated, I would consider catheter‑directed therapy or surgical embolectomy.”

• Demonstrate knowledge of dosing and contraindications and articulate the risk–benefit balance confidently.

9) Selected Study Resources and Guidelines (Keep Updating)

• UK guidelines: NICE NG158 (Venous thromboembolic diseases: diagnosis, management, and thrombophilia testing) and associated quality standards.

• European Society of Cardiology (ESC) Guidelines on acute pulmonary embolism (latest edition).

• BCSH/BSH guidance on anticoagulation and thrombolysis in acute PE.

• Recent literature (2023–2025) on catheter‑directed therapy, risk scores, and ECMO use in high‑risk PE.

• Recommended question banks and guideline summaries (e.g., Pastest, BMJ On Examination) with PE scenarios and echo clips for pattern recognition.

Massive PE is a clinical emergency. If you master the initial haemodynamic assessment, early echo, decisive reperfusion, and post‑thrombolysis anticoagulation, you’ll not only ace exam stations—you’ll save lives.